BACKGROUND: we performed the first test in humans of whether aspirin at clinically relevant doses increases nitric oxide (NO) formation. METHODS:seventy primary prevention patients with metabolic syndrome were randomly assigned to 81 mg, 162.5 mg, 325 mg, 650 mg, or 1300 mg aspirin daily for 12 weeks to test changes in heme oxygenase (HO-1), a downstream target of NO formation and asymmetrical dimethylarginine (ADMA), a competitive inhibitor of NO synthase. FINDINGS: for HO-1, the mean was 29.37 nanograms per milliliter at baseline and 57.45 at 12 weeks giving a mean ratio (MR) of 1.96 (P < .001) and 95% confidence interval (CI) from 1.91 to 2.00. There was no effect modification by dose or gender (P = .341). For ADMA, the mean was 1.70 micromoles per liter at baseline and 0.81 at 12 weeks, giving an MR of 0.48 (P < .001) and CI from 0.46 to 0.49. There was no effect modification by dose but a possible difference by gender (P = .055). INTERPRETATION: in high-risk primary prevention patients, aspirin significantly increases markers of NO formation. All doses produce similar increases in HO-1 and decreases in ADMA. The antiplatelet properties of aspirin to irreversibly inhibit platelet dependent cyclooxygenase are sufficient to explain benefits in patients with occlusive vascular diseases. Nonetheless, these data contribute to the formulation of the hypothesis that aspirin has additional beneficial effects mediated through NO formation. Further research, including direct randomized comparisons on atherosclerosis using noninvasive techniques as well as on occlusive vascular disease events, is necessary to test whether this hypothesis has clinical or public health relevance.
RCT Entities:
BACKGROUND: we performed the first test in humans of whether aspirin at clinically relevant doses increases nitric oxide (NO) formation. METHODS: seventy primary prevention patients with metabolic syndrome were randomly assigned to 81 mg, 162.5 mg, 325 mg, 650 mg, or 1300 mg aspirin daily for 12 weeks to test changes in heme oxygenase (HO-1), a downstream target of NO formation and asymmetrical dimethylarginine (ADMA), a competitive inhibitor of NO synthase. FINDINGS: for HO-1, the mean was 29.37 nanograms per milliliter at baseline and 57.45 at 12 weeks giving a mean ratio (MR) of 1.96 (P < .001) and 95% confidence interval (CI) from 1.91 to 2.00. There was no effect modification by dose or gender (P = .341). For ADMA, the mean was 1.70 micromoles per liter at baseline and 0.81 at 12 weeks, giving an MR of 0.48 (P < .001) and CI from 0.46 to 0.49. There was no effect modification by dose but a possible difference by gender (P = .055). INTERPRETATION: in high-risk primary prevention patients, aspirin significantly increases markers of NO formation. All doses produce similar increases in HO-1 and decreases in ADMA. The antiplatelet properties of aspirin to irreversibly inhibit platelet dependent cyclooxygenase are sufficient to explain benefits in patients with occlusive vascular diseases. Nonetheless, these data contribute to the formulation of the hypothesis that aspirin has additional beneficial effects mediated through NO formation. Further research, including direct randomized comparisons on atherosclerosis using noninvasive techniques as well as on occlusive vascular disease events, is necessary to test whether this hypothesis has clinical or public health relevance.
Authors: V Nascimento-Silva; M A Arruda; C Barja-Fidalgo; C G Villela; I M Fierro Journal: Am J Physiol Cell Physiol Date: 2005-05-18 Impact factor: 4.249
Authors: Nina Grosser; Aida Abate; Stefanie Oberle; Hendrik J Vreman; Phyllis A Dennery; Jan C Becker; Thorsten Pohle; Daniel S Seidman; Henning Schröder Journal: Biochem Biophys Res Commun Date: 2003-09-05 Impact factor: 3.575
Authors: Colin Baigent; Lisa Blackwell; Rory Collins; Jonathan Emberson; Jon Godwin; Richard Peto; Julie Buring; Charles Hennekens; Patricia Kearney; Tom Meade; Carlo Patrono; Maria Carla Roncaglioni; Alberto Zanchetti Journal: Lancet Date: 2009-05-30 Impact factor: 79.321
Authors: James Trauer; Stephen Muhi; Emma S McBryde; Shmeylan A Al Harbi; Yaseen M Arabi; Andrew J Boyle; Rodrigo Cartin-Ceba; Wei Chen; Yung-Tai Chen; Marco Falcone; Ognjen Gajic; Jack Godsell; Michelle Ng Gong; Daryl Kor; Wolfgang Lösche; Daniel F McAuley; Hollis R O'Neal; Michael Osthoff; Gordon P Otto; Maik Sossdorf; Min-Juei Tsai; Juan C Valerio-Rojas; Tom van der Poll; Francesco Violi; Lorraine Ware; Andreas F Widmer; Maryse A Wiewel; Johannes Winning; Damon P Eisen Journal: Crit Care Med Date: 2017-11 Impact factor: 7.598
Authors: Adil E Bharucha; Kyoung Moo Choi; Jessica J Saw; Simon J Gibbons; Gianrico F Farrugia; David A Carlson; Alan R Zinsmeister Journal: Neurogastroenterol Motil Date: 2014-07-29 Impact factor: 3.598
Authors: Scott Hetzel; David DeMets; Ricky Schneider; Steven Borzak; Wendy Schneider; Victor Serebruany; Henning Schröder; Charles H Hennekens Journal: J Cardiovasc Pharmacol Ther Date: 2013-03-21 Impact factor: 2.457
Authors: David B Liesenfeld; Akke Botma; Nina Habermann; Reka Toth; Christoph Weigel; Odilia Popanda; Karel D Klika; John D Potter; Johanna W Lampe; Cornelia M Ulrich Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-11-19 Impact factor: 4.254
Authors: Jason V Baker; Jacqueline Neuhaus; Daniel Duprez; Matthew Freiberg; Jose I Bernardino; Andrew D Badley; Daniel E Nixon; Jens D Lundgren; Russell P Tracy; James D Neaton Journal: J Acquir Immune Defic Syndr Date: 2012-06-01 Impact factor: 3.731
Authors: Damon P Eisen; Elizabeth M Moore; Karin Leder; Jessica Lockery; Emma S McBryde; John J McNeil; David Pilcher; Rory Wolfe; Robyn L Woods Journal: BMJ Open Date: 2017-01-20 Impact factor: 2.692
Authors: Tom Smith; Pippa Hutchison; Karsten Schrör; Joan Clària; Angel Lanas; Paola Patrignani; Andrew T Chan; Farhat Din; Ruth Langley; Peter Elwood; Andrew Freedman; Ron Eccles Journal: Ecancermedicalscience Date: 2015-10-13